Company intelligence / Profile preview
Tern Therapeutics
United Statesterntx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tern Therapeutics’ lead gene therapy candidate, TTX-381, is in a first-in-human Phase 1/2 clinical trial for CLN2 Batten disease with interim data indicating robust TPP1 expression, no serious adverse events, and preservation of photoreceptors at Day 90. TTX-181, aimed at CNS manifestations, has shown initial safety in an investigator-initiated study.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Gene therapyAdeno-associated viral vector therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
REGENXBIO (licensing partner)
Beyond the preview
Go deeper on Tern Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tern Therapeutics.